A team of engineers and biologists, Saphtx is structured around developing protein-based therapeutic strategies to address some important, currrent health issues. Approach is to address molecular design â> pan-coronavirus peptide drug â> Intranasal Spray to treat COVID-19 and variants. To date, the target has been defined (evolving Spike); a protein (peptide) that binds Spike has been designed. Drug has been characterized the drug and proven to work - blocking live-virus in vitro. Animal testing underway. Funds being raised to take this to clinic (GMP manufacturing and large animal DMPK). In the current context (late 2021), principals note that NO APPROVED DRUG exists for COVID-109 treatment outside hospital setting. Noting that re-purposed drugs have shown some clinical benefit, but have limitations, and are NOT APPOVED to treat non-hospitalized COVID-19 patients - Saphtx personnel are (currently) developing a rapidly scalable, cost-effective technology that is shown to block COVID-19 infection by âbindingâ or attaching specifically to SARS-CoV-2 and blocking its entry into human cells. Management suggest that the peptides (small proteins) theyare studying act like antibodies or complements what the human body naturally produces - binding to the SARS-CoV-2 virus, and targeting it for destruction. The hope is to create a safe and inexpensive therapeutic that will help reduce the spread and increase accessibility of treatment for CO